{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Bissa M"],"pubmed_abstract":["Simian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal infection with SIV<sub>mac251</sub> or Simian-Human immunodeficiency virus, respectively. Adding the Army Liposome Formulation + QS21 (ALFQ) adjuvant to the ΔV1gp120+Alum boost (ALFQA) may enhance protective immune responses. Here, we show that ALFQA protects 58% of female macaques from infection following eleven exposures to SIV<sub>mac251</sub>, achieving 79% vaccine efficacy. The ALFQA vaccine regimen augments mucosal CD73<sup>+</sup>CD163<sup>+</sup> M2-like macrophages and NKp44<sup>+</sup> innate lymphoid cells (ILCs), while reducing NKG2A<su"],"journal":["Nature communications"],"pagination":["8571"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12480912"],"repository":["biostudies-literature"],"pubmed_title":["HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques."],"pmcid":["PMC12480912"],"pubmed_authors":["Matyas GR","Goldfarbmuren KC","Washington-Parks R","Gutowska A","N'guessan KF","Kim J","Pise-Masison CA","Alving R","Cardozo T","McKinnon K","Basu S","Doster MN","Montefiori DC","Rahman MA","Rao M","Shen X","Sarkis S","Franchini G","Kanchetty NR","Silva de Castro I","Bissa M","Schifanella L","Woode EK","Paquin-Proulx D","Brown S"],"additional_accession":[]},"is_claimable":false,"name":"HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques.","description":"Simian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal infection with SIV<sub>mac251</sub> or Simian-Human immunodeficiency virus, respectively. Adding the Army Liposome Formulation + QS21 (ALFQ) adjuvant to the ΔV1gp120+Alum boost (ALFQA) may enhance protective immune responses. Here, we show that ALFQA protects 58% of female macaques from infection following eleven exposures to SIV<sub>mac251</sub>, achieving 79% vaccine efficacy. The ALFQA vaccine regimen augments mucosal CD73<sup>+</sup>CD163<sup>+</sup> M2-like macrophages and NKp44<sup>+</sup> innate lymphoid cells (ILCs), while reducing NKG2A<su","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T22:55:27.992Z","creation":"2026-05-02T03:11:51.261Z"},"accession":"S-EPMC12480912","cross_references":{"pubmed":["41022728"],"doi":["10.1038/s41467-025-63610-z"]}}